A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
Cugene Inc.
Summary
CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.
Description
The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Signed and dated informed consent. 2. Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor. 3. At least 1 measurable lesion according to RECIST v1.1. 4. Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 6. Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function. 7. Life expectancy of ≥3 months. 8. Female participants must not be pregnant or breastfeeding. Male parti…
Interventions
- BiologicalCUG279
CUG279 will be administered intravenously according to the protocol
Location
- NEXT VirginiaFairfax, Virginia